0001140361-15-011604.txt : 20150312 0001140361-15-011604.hdr.sgml : 20150312 20150312200023 ACCESSION NUMBER: 0001140361-15-011604 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20150310 FILED AS OF DATE: 20150312 DATE AS OF CHANGE: 20150312 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: OncoMed Pharmaceuticals Inc CENTRAL INDEX KEY: 0001302573 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 383572512 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 800 CHESAPEAKE DRIVE CITY: REDWOOD CITY STATE: CA ZIP: 94063 BUSINESS PHONE: 650-995-8200 MAIL ADDRESS: STREET 1: 800 CHESAPEAKE DRIVE CITY: REDWOOD CITY STATE: CA ZIP: 94063 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Dupont Jakob CENTRAL INDEX KEY: 0001553335 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35993 FILM NUMBER: 15697350 MAIL ADDRESS: STREET 1: C/O ONCOMED PHARMACEUTICALS, INC. STREET 2: 800 CHESAPEAKE DRIVE CITY: REDWOOD CITY STATE: CA ZIP: 94063 4 1 doc1.xml FORM 4 X0306 4 2015-03-10 0 0001302573 OncoMed Pharmaceuticals Inc OMED 0001553335 Dupont Jakob C/O ONCOMED PHARMACEUTICALS, INC. 800 CHESAPEAKE DRIVE REDWOOD CITY CA 94063 0 1 0 0 SVP & Chief Medical Officer Common Stock 2015-03-10 4 M 0 1500 4.56 A 23120 D Common Stock 2015-03-10 4 S 0 1500 27.1691 D 21620 D Stock Option (Right to Buy) 4.56 2015-03-10 4 M 0 1500 0.00 D 2021-10-24 Common Stock 1500 160437 D Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on May 27, 2014. Includes 20,000 restricted stock units. The Reporting Person is entitled to receive one (1) share of common stock for each one (1) restricted stock unit. This transaction was executed in multiple trades in prices ranging from $26.84 to $27.53, inclusive. The price reported in Column 4 above reflects the weighted average sales price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. The option was immediately exercisable in full on October 24, 2011; however, the shares vest pursuant to the following schedule: Twenty Percent (20%) of the shares subject to the option vest on the first anniversary measured from October 1, 2011 (the "Vesting Commencement Date") and the remaining shares subject to the option vest in 48 successive, equal monthly installments thereafter on each monthly anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date. /s/ Alicia J. Hager, Attorney-in-Fact for Jakob Dupont 2015-03-12